This result confirms AP1’s exclusive affinity for NCL compared to other targets at the cellular level and illustrates that both breast cancer cell lines exhibit similar competitive response patterns to AP1-NCL binding. This evidence concerns the gene NUCLEOLIN and breast carcinoma.